<DOC>
	<DOCNO>NCT01455493</DOCNO>
	<brief_summary>This multicenter , single-arm , open-label Phase II study evaluate activity GDC-0980 patient recurrent persistent endometrial cancer . The safety , tolerability , pharmacokinetics GDC-0980 also evaluate .</brief_summary>
	<brief_title>A Study GDC-0980 Treatment Recurrent Persistent Endometrial Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Patients must recurrent persistent endometrial carcinoma refractory curative therapy establish treatment Histologic confirmation original primary tumor require Histologic cytologic confirmation recurrent/progressive disease desire Patients must least one two prior chemotherapeutic regimen management endometrial carcinoma Disease measurable per RECIST v1.1 No active infection require antibiotic Any hormonal therapy direct malignant tumor must discontinue least 2 week prior first study treatment Any prior therapy direct malignant tumor , include immunologic agent radiotherapy , must discontinue least 2 week prior first study treatment Adequate hematologic end organ function Type I diabetes Type II diabetes require insulin Prior use mTOR/PI3K inhibitor Current dyspnea rest requirement supplemental oxygen therapy perform activity daily live Previous diagnosis pulmonary fibrosis cause History myocardial infarction unstable angina within 6 month prior first study treatment Congestive heart failure History malabsorption syndrome condition would interfere enteral absorption Clinically significant history liver disease , include cirrhosis current alcohol abuse Presence positive test result hepatitis B hepatitis C Known HIV infection Active autoimmune disease control nonsteroidal anti inflammatory drug Need current chronic corticosteroid therapy Pregnancy , lactation , breastfeed Current severe , uncontrolled systemic disease Major surgical procedure significant traumatic injury within 28 day prior Day 1 anticipation need major surgery course study treatment Uncontrolled hypercalcemia Leptomeningeal disease manifestation cancer Known untreated active brain metastasis Grade &gt; =2 hypercholesterolemia hypertriglyceridemia</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>